The role of intravenously administered vitamin C as a (possible) anticancer factor

 
Vitamin C has been researched since 1952 as a (possible) anticancer factor. The two-time Nobel Laureate Linus Pauling has been involved for years with the high intravenous dose of vitamin C in the battle against cancer. In many medical centers the administration of vitamin C is used as a complementary or palliative therapy as part of the effort for the best supportive care of the cancer patient. Intravenous administration is clearly advantageous as compared to oral administration because it is the only way to achieve the desired concentration in the body. The high doses of vitamin C administered intravenously have the following effects:

  a) Kill many forms of cancer cells (but not the normal ones
  b) Help radiotherapy and some forms of chemotherapy to act better
  c) Protect normal tissues from the toxicity of chemotherapy, thus reducing the complications of chemotherapy
  d) Strengthen the immune system
  e) Improve the quality of life (QOL) to cancer patients by reducing pain, increasing their energy and appetite
  f) They help in the battle against cancer complications such as the ascorbic acid deficiency observed in cancer patients and in the battle against coexisting inflammations of microbial – viral or fungal etiology.

The use of vitamin C for the treatment (care) of cancer patients has not been established as a necessary treatment yet , as research continues. The negative result of some research may be due to various other concomitant factors (and not to the action of vitamin C) such as hormonal, metabolic or electrolytic disorders such as magnesium poverty, smoking or excessive use of alcohol, the existence of heavy metals in the body, in the use of opioids, in dysbiosis, in increased stress. The above factors, if corrected, may improve the effectiveness of vitamin C. The administration of vitamin C does not have serious side effects and these are very rare with the main one being nephrolithiasis. Infusion is prohibited in patients who have a deficiency of the enzyme G-6PD.

Also to increase the effectiveness of vit C in the body the following are extremely important:

1. The high level of oxygen of the tissues:
   Tissue oxygenation can be increased either by ozone therapy (with a large autotransfusion or intestinal instigation of medical ozone) or by the use of hyperbaric oxygen.
2. 2) The value of glucose in the patient's blood:
   Hyperglycaemia competes with vit C . This means that the administration of vit C should be done in hungry patients and necessarily regulated any coexisting diabetes mellitus.
3. 3) The non-use of antioxidants:
   It is not recommended to simultaneously administer (along with high doses of vitamin C) antioxidant agents because these can neutralize its (pro)oxidative action and reduce the expected anticancer effect.
4. 4) The co-administration of Magnesium and the alkalopoiesis of the organism.
   

Dr. Lazaros Daniilidis , MD, MH , Ph. D
Surgeon, Doctor of Democritus University
Founding Member of The Greek Ιntegrative Oncology
and the Greek Society of Oncological Hyperthermia
Member of the Hellenic Ozone Therapy Society

------------------
Bibliography
------------------

1. Michael J Conzalcz , Jorge R. Miranda – Massari, Jorge Duconge , Miguel J. Berdiel Increasing the Effactiveness of Intravenous Vitamic C as an Anticancer Agent (Journal of orthomelecular medicine Vol30 NO 1 2015)
2. Enhanced Anticancer Effect of Adding Magnesium to vitamin C Therapy : Inhibition of Hormetic Response by SVCT-2 Activation Sungrue cho, Jin Sung Chae,Hocheol Shin, Yujeong Shin, Youngwook Kim, Eui-Joon Kil, Hee-Seong Byun, Sang-Ho Cho, Seyeon Park, Sukchan Lee, and Chang-Hwan Yeom , Transl Oncol 13(2)401-409(2020)
3. Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1976;73(10):3685-3689. 1PMC free article] 1 PubMed] [Google Scholar]
4. Cameron E., Pauling L. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci USA. 1978;75(9):4538-4542. rPMC free article] [PubMed] [Google Scholar]
5. ...